الفهرس 
INTRODUCTION AND OBJECTIVESOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
In spite of the advances in the use of chemotherapeutic agents in the treatment of acute ernia, development of resistance to the cytostatic drugs applied prevents cure in the majority of t atients. Therefore, an important part of today’s leukemia treatment research is focused on loping a new antileukemic agents. Dinaline [4_amino-N-(2’-aminophenyl)benzamide] was initially developed as a potential ’convulsive agent. Because it also showed reversible leukocytopenia, inhibition of rmatogenesis in rats and dogs, a cytostatic potential was suggested. Dinaline has extreme ’leukemic activity against the Brown Norwy rat acute myelocytic leukemia (BNML). etyldinaline [CI-994, GOE 5549, 4_acetylamine-N(2’-aminophenyl)-benzamide] is the active predominant metabolite of the parent compound Dinaline. Because genetic polymorphism in ans predicts a variable capacity of acetylation, this problem can be avoided by using etyldinaline which make the latter the relevant candidate for clinical trials in the near future. The BNML model has been recognized as one of the most realistic models for human acute emia (AML). It shows a reproducible growth pattern upon intravenous cellular transfer within Brown Norway rat strain. Cytologically and cytochemically BNML has similarities with human te pro myelocytic leukemia. Further analogies with the human disease are a slow growth rate, ere suppression of normal hemopoiesis and response to chemotherapy as in human AML.The L rat model has been used in the past to study the antileukemic effects of Dinaline. Because etyldinaline is the optimal candidate for clinical trials, the therapeutic index of Acetyldinaline eded to be studied in the BNML model. There were different situations in which Acetyldinaline We started by comparing the antileukemic activity of three Dinaline compounds at early ge leukemia (day 7) and comparing the antileukemic activity of Dinaline and Acetyldinaline at anced stage leukemia (day 13). The BNML rats were treated with equimolar doses of 10 g/day Dinaline, 11.85 mg/kg/day Acetyldinaline and 10.6 mg/kg/day Methyldinaline starting.